Luciano Costa, MD, Discusses Results From CARTITUDE-4 Subanalysis

Luciano Costa, MD, of the University of Alabama at Birmingham, at the 2024 ASCO® Annual Meeting in Chicago presents subgroup findings from the CARTITUDE-4 phase III trial.

Specifically, this analysis was of patients who received a single-line of therapy, who, Dr. Costa said, have “what we call dynamic high-risk or functional high-risk, which are patients who had progression within 18 months of the initial therapy or within 18 months of the autologous transplant used as upfront therapy.”

In their findings, Dr. Costa said “what we saw both for the one line of therapy population and for the functional high-risk population is that cilta-cel led to more frequent and deeper responses that also translate into much longer progression-free survival,” with no new safety signals.